Gefitinib Tablets IP 250mg
GEFLIEVA 250 MG (Gefitinib Tablets IP 250 mg) is a prescription targeted anticancer medicine containing Gefitinib 250 mg, which is primarily used for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). Gefitinib belongs to a class of medications known as Tyrosine Kinase Inhibitors (TKIs) that work by blocking specific proteins responsible for the growth and spread of cancer cells.
Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for the majority of lung cancer cases worldwide. Certain patients with NSCLC have specific EGFR gene mutations that cause uncontrolled cancer cell growth. GEFLIEVA 250 MG is specifically designed to target these mutations and inhibit the signaling pathways that promote tumor development and progression.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Gefitinib provides a more precise and targeted approach to cancer treatment. By directly targeting EGFR-positive cancer cells, it helps slow tumor growth while minimizing damage to normal tissues.
GEFLIEVA 250 MG is commonly prescribed for:
EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Advanced Lung Cancer
Metastatic Lung Cancer
Locally Advanced NSCLC
Recurrent Lung Cancer
First-Line Targeted Therapy for Eligible Patients
Precision Oncology Treatment Programs
Long-Term Cancer Management
Before starting treatment, healthcare professionals typically perform molecular testing to confirm the presence of EGFR mutations. This helps identify patients who are most likely to benefit from Gefitinib therapy.
Gefitinib has become an important part of modern precision oncology because it specifically targets cancer-driving genetic abnormalities. It is often prescribed as a first-line treatment for eligible patients and may also be used in certain advanced-stage cancer treatment plans.
Manufactured under stringent pharmaceutical quality standards, GEFLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Gefitinib therapy usually require routine monitoring, including clinical assessments, liver function tests, blood investigations, and regular follow-up appointments to evaluate treatment response and manage potential side effects.
Due to its targeted mechanism and proven clinical benefits, GEFLIEVA 250 MG remains an important treatment option for patients with EGFR-positive lung cancer worldwide.
View Details
Capecitabine Tablets IP 500mg
CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) is a prescription anticancer medicine containing Capecitabine 500 mg, an oral chemotherapy medication widely used for the treatment of various types of cancer, including colorectal cancer, breast cancer, gastric cancer, and other advanced solid tumors. Capecitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the growth and multiplication of cancer cells.
Capecitabine is considered a prodrug, meaning it is converted inside the body into 5-Fluorouracil (5-FU), a well-established anticancer agent. This conversion occurs more actively within tumor tissues, helping target cancer cells while reducing exposure to healthy tissues. As a result, CAPELIEVA 500 MG offers the convenience of oral administration while delivering the proven benefits of fluoropyrimidine-based cancer therapy.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. CAPELIEVA 500 MG helps slow or stop this process by disrupting DNA synthesis in rapidly dividing cancer cells, thereby reducing tumor growth and progression.
The medicine is frequently prescribed as a standalone therapy or in combination with other chemotherapy agents, targeted therapies, or radiation treatment depending on the type and stage of cancer.
CAPELIEVA 500 MG is commonly prescribed for:
Colorectal Cancer
Metastatic Colorectal Cancer
Breast Cancer
Metastatic Breast Cancer
Gastric (Stomach) Cancer
Advanced Gastrointestinal Cancers
Combination Chemotherapy Regimens
Long-Term Oncology Treatment Programs
One of the key advantages of Capecitabine is that it allows patients to receive chemotherapy treatment at home under the supervision of their oncologist, reducing the need for frequent hospital-based infusions.
Manufactured according to strict pharmaceutical quality standards, CAPELIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Capecitabine therapy require regular medical monitoring, including blood tests, liver and kidney function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven clinical effectiveness and convenient oral administration, CAPELIEVA 500 MG remains an important component of modern cancer treatment worldwide.
View Details
Abiraterone Acetate Tablets IP 500mg
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) is a prescription anticancer medicine containing Abiraterone Acetate 500 mg, a targeted hormonal therapy used primarily for the treatment of prostate cancer. It is commonly prescribed for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) as part of a comprehensive oncology treatment plan.
Abiraterone Acetate belongs to a class of medicines known as androgen biosynthesis inhibitors. Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, to grow and multiply. ABIRALIEVA 500 MG works by blocking an enzyme called CYP17 (17α-hydroxylase/C17,20-lyase), which plays a crucial role in the production of androgens in the testes, adrenal glands, and tumor tissues.
By significantly reducing androgen levels throughout the body, Abiraterone helps slow the growth and spread of prostate cancer cells. This targeted mechanism has made it one of the most important advances in the treatment of advanced prostate cancer.
Unlike conventional chemotherapy, Abiraterone specifically targets hormone production pathways associated with prostate cancer progression. It is frequently prescribed alongside corticosteroids such as prednisone or prednisolone to help manage certain treatment-related effects and optimize therapeutic outcomes.
ABIRALIEVA 500 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine has become a cornerstone of modern prostate cancer treatment due to its ability to improve disease control and support long-term management strategies.
Manufactured under stringent pharmaceutical quality standards, ABIRALIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy typically undergo regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical efficacy and targeted hormonal action, ABIRALIEVA 500 MG remains an important treatment option in advanced prostate cancer care worldwide.
View Details
Abiraterone Acetate Tablets IP 25mg
ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) is a prescription anticancer medicine containing Abiraterone Acetate 250 mg, a targeted hormonal therapy widely used in the treatment of advanced prostate cancer. It is specifically designed to help manage prostate cancers that depend on male hormones, known as androgens, for growth and survival.
Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, cancer cells continue to grow even after conventional hormone-lowering treatments. ABIRALIEVA 250 MG helps address this challenge by reducing androgen production throughout the body, thereby slowing cancer progression and helping improve treatment outcomes.
Abiraterone Acetate belongs to a class of medicines called Androgen Biosynthesis Inhibitors. It works by blocking the activity of the CYP17 enzyme, which plays a crucial role in the production of testosterone and other androgens in the adrenal glands, testes, and prostate tumor tissues. By significantly reducing androgen levels, the medicine helps limit the growth and spread of prostate cancer cells.
Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, Abiraterone targets hormone production pathways associated with cancer progression. This targeted mechanism has made it an important component of modern prostate cancer treatment strategies.
ABIRALIEVA 250 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Dependent Prostate Cancer
Long-Term Cancer Management
Combination Hormonal Therapy Programs
Precision Oncology Treatment Plans
The medicine is often used in combination with corticosteroids such as prednisone or prednisolone as recommended by healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ABIRALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy require regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted hormonal action, ABIRALIEVA 250 MG has become a trusted treatment option for advanced prostate cancer worldwide.
View Details
Palbociclib Capsules 125mg
PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) is a prescription targeted anticancer medicine containing Palbociclib 125 mg, an advanced CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used primarily for the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed as part of combination therapy with hormonal treatments to help slow cancer growth and improve treatment outcomes.
Breast cancer is one of the most common cancers affecting women worldwide. Certain breast cancers depend on hormones such as estrogen and progesterone for growth. In these cancers, abnormal cell cycle activity can cause uncontrolled tumor growth and disease progression. PALBOLIEVA 125 MG works by targeting proteins known as CDK4 and CDK6, which play a critical role in cell division and cancer cell proliferation.
By blocking these proteins, Palbociclib helps stop cancer cells from progressing through the cell cycle, thereby slowing tumor growth and delaying disease progression. This targeted mechanism has transformed the treatment landscape for HR-positive, HER2-negative advanced breast cancer and has become a standard component of modern oncology care.
Unlike conventional chemotherapy, Palbociclib specifically targets cancer growth pathways while working alongside hormone therapies such as aromatase inhibitors or fulvestrant. This precision-based approach allows for more effective disease control while helping maintain quality of life.
PALBOLIEVA 125 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is typically prescribed after careful evaluation by an oncologist and may be used in different stages of advanced breast cancer treatment depending on the patient's medical condition and treatment history.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 125 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function tests, infection assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 125 MG has become an important treatment option in modern breast cancer management worldwide.
View Details
Palbolieva Capsules 100mg
PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) is a prescription targeted anticancer medicine containing Palbociclib 100 mg, a highly effective CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used in the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed in combination with hormone therapies to help slow cancer progression, control tumor growth, and improve patient outcomes.
Breast cancer remains one of the most frequently diagnosed cancers worldwide. Many breast cancer cells rely on hormones such as estrogen for growth and survival. In HR-positive breast cancer, abnormal activation of cellular pathways can cause uncontrolled cell division and tumor progression. PALBOLIEVA 100 MG is specifically designed to target these pathways by blocking CDK4 and CDK6 proteins, which are essential for cancer cell multiplication.
By preventing cancer cells from progressing through critical stages of the cell cycle, Palbociclib helps reduce tumor growth and delay disease progression. This targeted mechanism has significantly improved treatment strategies for patients with advanced and metastatic hormone receptor-positive breast cancer.
Unlike traditional chemotherapy, which affects rapidly dividing healthy and cancerous cells alike, Palbociclib offers a more precise approach by targeting specific proteins involved in cancer cell proliferation. This allows it to work effectively alongside endocrine therapies such as aromatase inhibitors and fulvestrant.
PALBOLIEVA 100 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is often used as part of personalized treatment strategies developed by oncologists based on the patient’s cancer stage, medical history, and treatment goals.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function assessments, infection evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 100 MG has become an important treatment option in modern breast cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription anticancer medicine containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically designed to help slow the growth and spread of prostate cancer cells by blocking the effects of male hormones, known as androgens, that fuel cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells depend on testosterone and other androgens for survival and growth. Even after treatments that lower testosterone levels, cancer cells may continue to grow by activating androgen receptors. ENZALIEVA 40 MG helps overcome this challenge by directly blocking androgen receptor signaling, thereby reducing the ability of cancer cells to multiply and spread.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors. Unlike conventional hormone therapies that primarily reduce testosterone production, Enzalutamide works by preventing androgen receptors from receiving hormonal signals. This dual approach helps provide more effective disease control in advanced stages of prostate cancer.
ENZALIEVA 40 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Long-Term Prostate Cancer Management
Hormone-Driven Prostate Tumors
Precision Oncology Treatment Programs
The medicine may be used as part of a comprehensive cancer treatment plan developed by an oncologist based on the patient's medical condition, disease stage, and treatment history.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Enzalutamide therapy typically require regular monitoring, including blood pressure assessments, liver function evaluations, neurological monitoring, and routine clinical follow-up to ensure safe and effective treatment.
Due to its targeted mechanism of action and proven clinical benefits, ENZALIEVA 40 MG has become an important treatment option in modern prostate cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription medication containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically developed to help control the growth and spread of prostate cancer cells by blocking the effects of male hormones (androgens) that play a crucial role in cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. While many prostate cancers initially respond to hormone-lowering therapies, some cancers eventually continue to grow despite reduced testosterone levels. ENZALIEVA 40 MG helps address this challenge by directly targeting androgen receptor signaling pathways that cancer cells rely on for survival and multiplication.
Enzalutamide works differently from traditional hormone therapies. Instead of only reducing hormone production, it blocks the androgen receptor at multiple stages, preventing cancer cells from receiving and using hormonal signals. This advanced mechanism helps slow tumor growth, delay disease progression, and support long-term disease management.
ENZALIEVA 40 MG is widely prescribed for patients with:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Precision Oncology Treatment Programs
The medicine has become an important part of modern prostate cancer treatment because of its proven ability to improve progression-free survival and help maintain quality of life in eligible patients.
Unlike conventional chemotherapy, ENZALIEVA 40 MG specifically targets pathways involved in prostate cancer growth, making it a highly effective option for selected patients. It is often prescribed as part of a comprehensive oncology treatment plan under the supervision of experienced healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Regular follow-up appointments, laboratory testing, and clinical evaluations are important during treatment to monitor effectiveness and manage any potential side effects.
View Details
Olaparib Tablets 150mg
PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) is a prescription targeted anticancer medicine containing Olaparib 150 mg, a highly advanced PARP (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of several types of cancer associated with specific genetic mutations, particularly BRCA1 and BRCA2 mutations. Olaparib is widely used in modern precision oncology to help slow cancer growth, delay disease progression, and improve treatment outcomes in eligible patients.
Cancer cells with BRCA gene mutations often have difficulty repairing damaged DNA. PARIBLIEVA 150 MG works by blocking PARP enzymes, which cancer cells use to repair their DNA. When both repair mechanisms are disrupted, cancer cells are unable to survive and eventually die. This targeted approach allows Olaparib to selectively attack cancer cells while minimizing damage to healthy tissues.
PARIBLIEVA 150 MG has become an important treatment option in personalized cancer care and is commonly prescribed for patients whose tumors carry specific genetic abnormalities. Genetic testing is often performed before treatment to determine whether a patient is likely to benefit from Olaparib therapy.
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, Olaparib specifically targets cancer cells with defective DNA repair pathways. This precision-based mechanism has transformed the treatment landscape for several difficult-to-treat cancers.
PARIBLIEVA 150 MG is commonly prescribed for:
BRCA-Mutated Ovarian Cancer
Advanced Ovarian Cancer
Recurrent Ovarian Cancer
BRCA-Mutated Breast Cancer
HER2-Negative Breast Cancer with BRCA Mutation
Metastatic Breast Cancer
Pancreatic Cancer with BRCA Mutation
Metastatic Pancreatic Cancer
Prostate Cancer with Homologous Recombination Repair (HRR) Gene Mutations
Precision Oncology Treatment Programs
The medicine may be used as maintenance therapy after successful cancer treatment or as part of long-term disease management plans, depending on the patient's condition and oncologist’s recommendations.
Manufactured according to stringent pharmaceutical quality standards, PARIBLIEVA 150 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Olaparib therapy require routine monitoring, including blood tests, kidney and liver function assessments, and regular clinical evaluations to ensure safe and effective treatment.
Due to its targeted mechanism and proven clinical benefits, PARIBLIEVA 150 MG has become a valuable treatment option in modern cancer care worldwide.
View Details
Lenvatinib Capsules 10mg
LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) is a prescription targeted anticancer medicine containing Lenvatinib 10 mg, an advanced multi-kinase inhibitor used for the treatment of several types of cancer. It is commonly prescribed for patients with thyroid cancer, liver cancer, kidney cancer, and endometrial cancer, helping to slow tumor growth, delay disease progression, and improve treatment outcomes.
Lenvatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs). It works by blocking specific proteins involved in tumor growth and blood vessel formation. Cancer cells require a continuous blood supply to receive oxygen and nutrients needed for growth. LENVALIEVA 10 MG helps prevent the formation of new blood vessels that feed tumors, thereby limiting cancer progression.
Unlike conventional chemotherapy, which attacks rapidly dividing cells throughout the body, Lenvatinib specifically targets pathways involved in cancer growth and angiogenesis (blood vessel formation). This targeted approach has made it an important component of modern oncology treatment strategies.
LENVALIEVA 10 MG is commonly prescribed for:
Differentiated Thyroid Cancer (DTC)
Radioactive Iodine-Refractory Thyroid Cancer
Hepatocellular Carcinoma (Liver Cancer)
Advanced Renal Cell Carcinoma (Kidney Cancer)
Advanced Endometrial Cancer
Metastatic Solid Tumors (Selected Cases)
Targeted Oncology Treatment Programs
Long-Term Cancer Management
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, disease stage, and treatment goals.
Lenvatinib has become a valuable treatment option because it targets multiple pathways involved in cancer progression, helping improve disease control in patients with advanced cancers.
Manufactured according to stringent pharmaceutical quality standards, LENVALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenvatinib therapy require routine medical monitoring, including blood pressure assessments, liver function tests, kidney function evaluations, thyroid monitoring, and regular clinical examinations.
Due to its targeted mechanism and broad clinical applications, LENVALIEVA 10 MG plays an important role in modern cancer care worldwide.
View Details
Lenvatinib Capsules 4mg
LENVALIEVA 4 mg contains Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). It inhibits multiple receptors involved in tumor growth and angiogenesis, including VEGFR 1–3, FGFR 1–4, PDGFR-α, RET, and KIT, thereby suppressing tumor vascularization and proliferation.
View Details
Eltrombopag Olamine Tablets 50mg
TROMLIEVA 50 MG (Eltrombopag Olamine Tablets 50 mg) is a prescription medicine containing Eltrombopag Olamine 50 mg, a thrombopoietin receptor agonist used to increase platelet production in patients with certain blood disorders. It is commonly prescribed for individuals with chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C under the supervision of a qualified healthcare professional.
Platelets are blood cells that play a vital role in blood clotting and preventing excessive bleeding. When platelet levels become too low, patients may experience symptoms such as easy bruising, prolonged bleeding, frequent nosebleeds, bleeding gums, or tiny red spots on the skin known as petechiae. TROMLIEVA 50 MG helps address this problem by stimulating the body’s natural platelet production process.
Eltrombopag works by activating thrombopoietin receptors located in the bone marrow. These receptors are responsible for signaling the production of platelets. By stimulating these receptors, TROMLIEVA 50 MG helps increase platelet counts and reduce the risk of bleeding complications.
Unlike platelet transfusions, which provide a temporary increase in platelet levels, Eltrombopag encourages the body to produce its own platelets, making it a valuable option for long-term management in eligible patients.
TROMLIEVA 50 MG is commonly prescribed for:
Chronic Immune Thrombocytopenia (ITP)
Severe Aplastic Anemia
Low Platelet Counts Due to Chronic Hepatitis C
Bone Marrow Failure Disorders
Platelet Support During Treatment Programs
Long-Term Management of Thrombocytopenia
Hematology Treatment Protocols
Blood Disorder Management Programs
The medicine is often recommended when other treatments have not provided adequate platelet improvement or when long-term platelet support is required.
Manufactured according to stringent pharmaceutical quality standards, TROMLIEVA 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require routine blood tests, platelet count monitoring, liver function assessments, and regular medical evaluations to ensure safe and effective treatment.
Due to its proven ability to increase platelet production, TROMLIEVA 50 MG has become an important treatment option in modern hematology care.
View Details
